Speaking of calculations and the nearest contractual deal looming (MPS asset), has anyone ran the numbers on its potential?
It looks like Zilosul is conducive to working with both enzyme replacement therapy and bone marrow transplant patients safely and effectively.
We are duly focussed on the OA indication, but we have a smoky to consider too.
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-236
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10756 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 62010 | 3 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |